World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ChiCTR
Last refreshed on: 12 April 2021
Main ID:  ChiCTR2000040991
Date of registration: 2020-12-16
Prospective Registration: Yes
Primary sponsor: The First Affiliated Hospital, College of Medicine, Zhejiang University
Public title: Cyclosporine A combined with eltrombopag in the treatment for primary immune thrombocytopenia: a prospective, multicenter, single-arm, open clinical study
Scientific title: Cyclosporine A combined with eltrombopag in the treatment for primary immune thrombocytopenia: a prospective, multicenter, single-arm, open clinical study
Date of first enrolment: 2022-03-02
Target sample size: experimental group:28;
Recruitment status: Recruiting
URL:  http://www.chictr.org.cn/showproj.aspx?proj=65311
Study type:  Interventional study
Study design:  Single arm  
Phase:  4
Countries of recruitment
China
Contacts
Name: Jie Jin   
Address:  79 Qingchun Road, Hangzhou, Zhejiang 310003
Telephone: +86 13505716779
Email: jiej0503@163.com
Affiliation:  The First Affiliated Hospital, College of Medicine, Zhejiang University
Name: Chao Hu   
Address:  79 Qingchun Road, Hangzhou, Zhejiang 310003
Telephone: +86 13758188065
Email: zjuhuchao@163.com
Affiliation:  The First Affiliated Hospital, College of Medicine, Zhejiang University
Key inclusion & exclusion criteria
Inclusion criteria: 1. Aged 18~75 years;
2. Meet the diagnostic criteria of adult primary ITP;
3. Glucocorticoid therapy is ineffective, intolerant or recurring, and second-line treatment is required;
4. Platelet count < 20 x 10^9/L;
5. ECOG score <= 2;
6. Patients who are willing to receive treatment and sign an informed consent form.

Exclusion criteria: 1. Have a history of bone marrow stem cell abnormalities or observe other bone marrow abnormalities other than ITP-specific changes;
2. Combined with malignant tumors, active infections, other autoimmune diseases such as SLE, Sjogrens syndrome;
3. Received other ITP medications (including emergency treatment) within 2 weeks before the first administration (a stable dose of glucocorticoid, CsA, azathioprine, danazol, mycophenolate mofetil and other drugs before the first administration =4 Except for weeks);
4. Use Revolade (Eltrombopag) or Nplate (Romigrastim) or recombinant human thrombopoietin (rhTPO) or other c-Mpl (thrombopoietin receptor) stimulating drugs within 4 weeks before the first administration;
5. Received Decitabine within 4 weeks before the first dose;
6. Received splenectomy within 12 weeks before the first administration;
7. Received rituximab within six months before the first administration;
8. Have used the combination of CsA and Eltrombopag;
9. During the screening period, serum creatinine concentration> normal range, total bilirubin > 1.5 times the upper limit of normal range, alanine aminotransferase or aspartate aminotransferase> 3 times the upper limit of normal;
10. Have a history of blood clots or are using anticoagulant drugs;
11. Women during pregnancy and lactation;
12. Screening for hepatitis C antibodies, human immunodeficiency virus antibodies, or syphilis antibodies is positive;
13. Hepatitis B surface antigen positive or hepatitis B core antibody positive and HBV-DNA positive;
14. The researcher believes that it is not suitable for enrollment.


Age minimum: 18
Age maximum: 75
Gender: Both
Health Condition(s) or Problem(s) studied
primary immune thrombocytopenia
Intervention(s)
experimental group:Cyclosporine A combined with eltrombopag;
Primary Outcome(s)
Overall response rate;
Secondary Outcome(s)
Secondary ID(s)
???(101)?
Source(s) of Monetary Support
self-raised
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 23/09/2020
Contact:
??
Huili Zhou
+86 0571-611616
??
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey